New Patent Bolsters Anixa’s CAR-T Therapy for Solid Tumors Anixa Biosciences has received a U.S. patent for its CAR-T technology, specifically addressing solid tumors like ovarian cancer. The patent, licensed from The Wistar Institute, secures foundational methods for this therapy, which is currently in clinical trials, strengthening Anixa’s competitive edge in immunotherapy.78